Ruthenium Single‐Atom Nanozyme Driven Sonosensitizer with Oxygen Vacancies Enhances Electron–Hole Separation Efficacy and Remodels Tumor Microenvironment for Sonodynamic‐Amplified Ferroptosis
Sonodynamic therapy (SDT) has emerged as a promising noninvasive approach for tumor therapy. However, the effectiveness of traditional inorganic semiconductor sonosensitizers is hindered by rapid electron (e<sup>-</sup>) and hole (h<sup>+</sup>) recombination under ultrasonic (US) stimulation, as well as the hypoxic and reductive conditions of tumor microenvironment (TME), which limit the generation of reactive oxygen species (ROS). Herein, a ruthenium (Ru) single-atom nanozyme-driven superimposition-enhanced titanium dioxide-based sonosensitizer (Ru/TiO<sub>2-x</sub> SAE) is presented that features sufficient oxygen vacancies and high e<sup>-</sup>/h<sup>+</sup> separation efficiency. Through synchrotron radiation-based X-ray absorption spectroscopy and extended X-ray absorption fine structure analysis it is confirmed that oxygen vacancies in TiO<sub>2-x</sub> nanoparticles promote the immobilization of single-atomic Ru, forming Ru-O₄ active sites. Density functional theory calculations demonstrate that oxygen vacancies alter the electronic structure of nanosensitizer, enhanced e<sup>-</sup>/h<sup>+</sup> separation, increasing oxygen adsorption, and accelerating reaction kinetics under US stimulation, ultimately improving ROS production. Moreover, Ru/TiO<sub>2-x</sub> SAE boosts sonodynamic efficacy by mitigating the hypoxic and reductive TME. This is attributed to its catalase- and glutathione peroxidase 4-like activities, which facilitate the generation of ROS and trigger lipid peroxidation-mediated ferroptosis. These findings highlight the innovative role of single-atom Ru in optimizing sonosensitizers for SDT-induced ferroptosis, demonstrating its potential for advancing cancer therapy.
Authors
- Lisen Lin (ORCID: https://orcid.org/0000-0003-4060-8881)
- Penghui Wei (ORCID: https://orcid.org/0000-0003-0920-2779)
- Lichao Su (ORCID: https://orcid.org/0000-0001-9864-5904)
- Shunzhe Zheng
- Yi Hu (ORCID: https://orcid.org/0000-0003-2005-0913)
- Yang Zhu (ORCID: https://orcid.org/0000-0002-4747-9130)
- Lingjun Yan
- Dengliang Wang
- Chenyu Ding (ORCID: https://orcid.org/0000-0003-2358-1699)
- Huimin Wang (ORCID: https://orcid.org/0000-0002-3955-3687)
- Xiaoyuan Shawn Chen (ORCID: https://orcid.org/0000-0002-9622-0870)
- G. Li
- Tiantian Wu (ORCID: https://orcid.org/0000-0003-2300-375X)
- Hui Zheng (ORCID: https://orcid.org/0009-0000-2308-126X)
- Chengzhong Du
Institutions
- Fujian Medical University (CN)
- National University of Singapore (SG)
- First Affiliated Hospital of Fujian Medical University (CN)
- Hainan Medical University (CN)
Publication Details
- Journal
- Advanced Science
- Published
- 2025-04-25
- DOI
- https://doi.org/10.1002/advs.202416997
- Citations
- 34
- Primary Topic
- Nanoplatforms for cancer theranostics
- Type
- article
- Field-Weighted Citation Impact
- 22.92
Funders
- National University of Singapore
- National Natural Science Foundation of China
- Ministry of Education, India
- Bộ Giáo dục và Ðào tạo
- Medical Research Council
- National Medical Research Council